HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 2,053-2,064 of 4,505
Drug study icon
CompletedNCT00723606

Intramuscular Ziprasidone for Schizophrenia

What is this study about?

Researchers compared Intramuscular ziprasidone mesylate and Intramuscular haloperidol, tracking side effects to assess safety and tolerability in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Baoding
SchizophreniaMedication studyAges 18–65
Countries
China
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Other study type icon
CompletedNCT04655287

A Register Study of Effects Following Local Variation in Rates of Involuntary Care

Official study title

Do Low Rates of Coercion in Catchment Areas Predict Negative Effects for Persons With Severe Mental Disorders? A Register Study From Norway 2015-2017. Part of Reducing Coercion in Norway (ReCoN)

This study has finished and is no longer accepting participants.

Location not clearly listed
Schizophrenia, BipolarityObservational studyAges 18–65
Countries
Sponsor
University Hospital, Akershus
Drug study icon
TerminatedNCT00929370

A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and people with Schizophrenia and to Evaluate Its Effect on PK of Midazolam.

Official study title

A 4-Part Parallel Group, Randomized, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Repeat Doses of GSK1018921 in Healthy Volunteers and Stable Patients With Schizophrenia and to Evaluate Its Effects on Pharmacokinetics of Midazolam.

This study ended early.

Multiple locations, including Glendale
SchizophreniaMedication studyAges 18–55
Countries
United States
Sponsor
GlaxoSmithKline
Other study type icon
CompletedNCT01214135

Use of Seroquel Extended Release (XR) and Immediate Release (IR) for schizophrenia

Official study title

A Retrospective, Non-interventional Study to Evaluate the Use of Seroquel XR and Seroquel IR in the Clinical Practice of Inpatients With Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Falköping
SchizophreniaObservational studyAges 18–65
Countries
Sweden
Sponsor
AstraZeneca
Drug study icon
CompletedNCT01150448

A Safety and Pharmacokinetic Study of Paliperidone Palmitate in people with Schizophrenia

Official study title

An Open-Label, Long-Term, Multiple-Dose, Safety and Tolerability, Pharmacokinetic Study of 150 mg eq. Paliperidone Palmitate in the Treatment of Subjects With Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Cerritos
SchizophreniaMedication studyAges 18–65
Countries
United States, Belgium, Croatia, + 7 others
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT00119756

Safety study of paliperidone Palmitate Injected in schizophrenia

What is this study about?

This study evaluated the safety of paliperidone palmitate for people with schizophrenia.

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18+
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT00845026

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

What is this study about?

Researchers compared LY2140023, aripiprazole, olanzapine and risperidone, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Escondido
SchizophreniaMedication studyAges 18–65
Countries
United States, Germany, Mexico, + 1 other
Sponsor
Denovo Biopharma LLC
Drug study icon
CompletedNCT03565068

Safety study of MK-8189 in schizophrenia

Official study title

A Multiple-dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and QTc Effect of MK-8189 in Participants With Schizophrenia and Healthy Participants.

This study has finished and is no longer accepting participants.

In Glendale
SchizophreniaMedication studyAges 18–60
Countries
United States
Sponsor
Merck Sharp & Dohme LLC

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.